Plasma calcitonin gene-related peptide (CGRP) in migraine and endometriosis during the menstrual cycle

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of endometriosis and migraine in this observational study publication.

Migraine, endometriosis, and the comorbidity of both are frequent pain disorders of special relevance for women.

The researchers assessed CGRP levels at different times of menstrual cycle in four groups: healthy women, women with migraine or endometriosis and with the comorbidity of both.

Who Took Part

The age groups tagged for this paper are adults, women only.

Women with episodic migraine and women with a histologically confirmed endometriosis were recruited from specialized centers.

For CGRP determination with a commercial enzyme immunoassay kit, cubital vein blood samples were collected on menstrual cycle day 2 ± 2 (during menstruation) and on day 15 ± 2 (periovulatory period).

How the Study Was Run

The primary endpoint of the study was the absolute difference of CGRP plasma levels between the menstrual and the periovulatory phase of all study groups.

Groups were compared using nonparametric test procedures.

What Was Measured

The subject headings attached to it are Calcitonin Gene-Related Peptide, Comorbidity, Endometriosis, Longitudinal Studies, Menstrual Cycle, Migraine Disorders and Peptide Fragments.

What This Means in Plain Language

This is an observational study of CGRP (Calcitonin Gene-Related Peptide) in people with endometriosis.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Annals of clinical and translational neurology), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Endometriosis research, Migraine research.